Ovid Therapeutics Inc.
OVID · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -97.9% | 4,724.6% | 71.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 87.1% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9,197.7% | -79.3% | -9,545.4% | -14,160.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9,210.6% | -74.7% | -7,873.1% | -12,175% |
| EPS Diluted | -0.17 | -0.066 | -0.14 | -0.13 |
| % Growth | -158% | 52.9% | -7.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |